Clinical trial
A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy
The primary objective is to assess the treatment effect on progression-free survival (PFS) in patients who receive AUY922 on a once-weekly schedule versus patients who receive docetaxel or irinotecan.
| Category | Value |
|---|---|
| Study start date | 2010-07-01 |